Orthofix Medical Inc.

Thank you for standing by. At this time, I would like to welcome everyone to the OrthoFix first quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. We do ask questions be limited to one question and a brief related follow-up. Thank you. I would now like to turn the call over to Julie Dooley.

Thank you and good morning, everyone. Welcome to OrthoFix's first quarter 2026 earnings call. I'm Julie Dooley, OrthoFix's Chief IR and Communications Officer. Joining me today are President and Chief Executive Officer Massimo Calafiori and Chief Financial Officer Julie Anders. Earlier today, OrthoFix released its financial results for the first quarter ended March 31, 2026. A copy of the press release and supplemental presentation are available on our investor relations website, and a replay of this call will be posted shortly after we conclude. Before we begin, please note that our remarks include forward-looking statements. These statements involve risks and uncertainties, and actual results may differ materially. All statements other than those of historical facts are forward-looking statements. We do not undertake any obligation to revise or update such forward-looking statements. Factors that could cause actual results to differ materially are discussed in our most recent filings with the SEC and may be included in our future filings with the SEC. We will also reference various non-GAAP financial measures during today's call. Reconciliations to U.S. GAAP and additional details are in our press release and supplemental materials. Unless otherwise stated, net sales growth rates are on a pro forma constant currency basis and exclude the discounted M6 artificial disc product lines, and all results of operations will be on a non-GAAP as adjusted basis. Here's today's agenda. Massimo will start with business performance and operational highlights. Julie Andrews will follow with our financial results and guidance. Then we'll open up the call for Q&A. With that, I'll turn the call over to Massimo, who will discuss how our early year execution and recent operational actions are beginning to support improved performance as we move through the year. Massimo?

Thank you, Julie, and good morning, everyone. I appreciate you joining us today. We delivered a good start to 2026. First quarter results reflect steady execution, improving stability, and sharper strategic focus. As the quarter progressed, we began seeing the expected progress from our spine commercial channel actions along with stronger operating discipline, supporting our confidence that performance will continue to build through the year. While these results reflect meaningful progress, they also crystallize where we could further raise the bar. That's why, in April, we took deliberate steps to simplify our spine leadership structure, a proactive move as we continue to scale enabling technologies like 7D, and advance the launch of Virada later this year. By bringing decision-making closer to the field and increasing accountability through direct oversight, we're improving speed, consistency, and commercial focus, where it matters the most. Stepping back, Q1 reflects where we are as a company today. moving into the next phase of our journey, executing with greater consistency and strengthening our proposition to benefit from our innovation pipeline as the year unfolds. What we deliver this quarter supports our confidence in continued improvement. Our priorities are straightforward. execute consistently, convert opportunity into results, and demonstrate progress quarter by quarter. Let me turn to business performance highlights, starting with Spine. In Spine, global Spine fixation net sales grew 6% on a constant currency basis, with U.S. net sales growth of 4%. Results were supported by enhanced commercial focus, deeper procedural penetration, and the ongoing benefits of our distributor transitions. Importantly, those transitions are now largely behind us. As alignment has improved, we are seeing positive momentum from more consistent field executions. In Q1, our top 30 distributor partners delivered net sales growth of 27% year-over-year and 24% on trailing 12-month basis, reflecting the success of our strategy through prioritized, larger, more dedicated distributors and deeper relationships with our top partners. A key driver of that momentum is 7D, which remains a core differentiator in our surgical ecosystem, enhancing precision, workflow, and surgeon engagement. Following our leadership realignment, we are intensifying our commercial focus on adoption of our 7D flash navigation system to deliver a more integrated spine offering. While spine is benefiting from better alignment, we are applying the same discipline to biologics. Performance improved sequentially during the quarter as we implemented targeted actions to strengthen execution, expand account penetration, and increase utilization across the portfolio. we are refining our go-forward strategy, building clinical evidence and supporting advocacy. Collectively, these actions are designed to drive improvement through the year and position biologics to exit 2026 with stronger momentum and a more durable growth profile. Beyond spine and biologics, Our other growth platforms remained resilient. Our therapeutic solution business, formerly Bonn Growth Therapies, delivered 5% year-over-year net sales growth and continued to outperform the broader market. Demands remained stable, utilization is improving, and prescribing activities increasing across both pine fusion and fracture care. With its consistent performance and healthy margins, this business continues to be an important contributor to margin and cash generation. Global rim reconstruction post a 3% constant currency growth, reflecting steady demand across our core fixation and reconstruction systems. Over the past year, we sharpened our focus by prioritizing high-value categories, enhancing our mix with platforms like TrueLock Elevate and Fitbon, and de-emphasizing lower return products. We believe this action position limb reconstruction for acceleration as we move through 2026. A common thread across the business is the increasing impact of our innovation pipeline. We will have a full year contribution from Truelock Elevate and Fitborn, and we remain on track for the full market launch of Virata in the second half of the year. Together with the continued expansion of our 7D flash ecosystem, these platforms are designed to deliver differentiated clinical value and support durable multi-year growth. In closing, Q1 was a solid start of the year. We are carrying that momentum forward with disciplined execution and targeted investment. The quality and the commitment of our US spine distributors greater than ever and meaningfully contributing to our success. Our innovation pipeline is strong, our operating model is more focused and we believe we have the right team and the financial foundation in place. There is more work to do and we are increasingly confident in our ability to execute, doing fewer things better and sharpening accountability, generating cash, and delivering on what we said we would do. With that, I'll turn the call over to Julie Andrews to review our financial results and guidance.